A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 40
- Population
- ALL · 55 Years to 89 Years
- Duration
- 2021-08-11 to 2027-03-05
- Intervention
- Rapamycin; Placebo
- Comparator
- RAPA (rapamycin) treatment group; Placebo group
- Outcomes measured
- Number of adverse events — Baseline to 12 months; Change in glucose level — Baseline to 12 months; Change in albumin — Baseline to 12 months; Change in carbon dioxide or bicarbonate (CO2) — Baseline to 12 months; Change in calcium — Baseline to 12 months; Central nervous system penetration of rapamycin — Baseline and 12 months; Change in Cognition using preclinical Alzheimer's Cognitive Composite 5 (PACC5) — Baseline to 12 months; Change in Cognition using Clinical Dementia Rating Scale sum of Boxes (CDR-SOB) — Baseline to 12 months; Change in Functional status — Baseline to 12 months; Change in Neuropsychiatric symptoms — Baseline to 12 months; Change in Gait Speed — Baseline to 12 months; Change in Grip Strength — Baseline to 12 months; Change in CSF amyloid beta — Baseline to 12 months; Change in cerebral glucose metabolism — Baseline to 12 months; Change in Brain Volumetry — Baseline to 12 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.